Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX) released its earnings results on Monday. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06), FiscalAI reports. The firm had revenue of $83.30 million for the quarter, compared to analysts’ expectations of $81.80 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The firm’s quarterly revenue was up 81.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.70) EPS.

Here are the key takeaways from Syndax Pharmaceuticals’ conference call:

• Revuforj revenue reached $60.7 million, up 90% year over year and 11% sequentially, with new patient starts rising 20% and prescriptions increasing 13%. Syndax said it maintains dominant share across menin-inhibitor starts and has expanded to more than 620 prescribing accounts.
• Revuforj’s use in NPM1 and KMT2A acute leukemia is increasingly bridging patients to stem-cell transplant, with roughly 40% of NPM1 patients and 50% of KMT2A patients proceeding to transplant. About 50% of NPM1 and 60% of KMT2A patients have resumed therapy afterward, which management expects to become a larger growth driver in 2027 as post-transplant treatment accumulates.
• Niktimvo net revenue increased 47% year over year to $67 million, generating $22.6 million of collaboration revenue for Syndax and lifting its expected margin contribution to the low- to mid-30% range. The company is also advancing frontline chronic GVHD combination trials that could substantially expand the product’s market opportunity.
• Syndax expects multiple clinical catalysts, including expanded frontline Revuforj combination data and real-world evidence at ASH, NUP98 leukemia data in the fourth quarter, and axatilimab frontline results in the first quarter of 2027. Its EGFR inhibitor and next-generation menin inhibitor remain on track to enter clinical development next year.
• The company ended the quarter with $551 million in cash and reiterated approximately $400 million of 2026 R&D and SG&A expenses, saying it is funded through its current priorities. CFO Keith Goldan will retire, with Aaron Ondrey scheduled to succeed him on November 9, 2026; management did not provide updated timing for frontline Revuforj enrollment completion or approval.

Syndax Pharmaceuticals Trading Down 4.0%

Shares of SNDX stock opened at $13.10 on Tuesday. Syndax Pharmaceuticals has a 1 year low of $12.80 and a 1 year high of $25.59. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44. The stock’s 50 day simple moving average is $17.05 and its two-hundred day simple moving average is $20.21. The company has a market cap of $1.16 billion, a PE ratio of -5.22 and a beta of 0.42.

Insider Activity at Syndax Pharmaceuticals

In other news, Director Dennis Podlesak sold 8,000 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $14.21, for a total value of $113,680.00. Following the completion of the transaction, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. The trade was a 3.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.80% of the company’s stock.

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 82% year over year to $83.3 million, exceeding the $81.8 million analyst consensus. Revuforj revenue increased 90% to $60.7 million, supported by 20% sequential growth in new patients, while Niktimvo net revenue reached $67.4 million, up 47% year over year. Syndax third-quarter 2026 financial results
• Positive Sentiment: Management highlighted upcoming Revuforj data from clinical and real-world studies in the fourth quarter, while commentary pointed to a rebound in Revuforj and improved Niktimvo margin expectations—potential catalysts for future growth and profitability. Syndax commercial update and pipeline analysis
• Positive Sentiment: Brokerages maintain a consensus price target of $41.80, implying substantial potential upside from recent trading levels and supporting the view that the stock may be undervalued. Syndax consensus price target
• Neutral Sentiment: Aaron A. Ondrey will become chief financial officer on November 9. Outgoing CFO Keith Goldan will remain through year-end to assist with the transition. Syndax CFO transition
• Negative Sentiment: Syndax reported a third-quarter loss of $0.55 per share, worse than the $0.49–$0.52 consensus range, although the loss improved from $0.70 per share a year earlier. The earnings miss likely pressured the stock. Syndax third-quarter earnings
• Negative Sentiment: Investors remain concerned about pipeline setbacks and Syndax’s continuing losses, with analysts forecasting a full-year loss of approximately $2.01 per share. The company’s negative net margin and return on equity reinforce profitability risks. Syndax Q3 valuation analysis

Analyst Ratings Changes

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. lowered their price objective on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. Bank of America reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. Weiss Ratings cut Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 19th. Finally, Mizuho set a $43.00 price target on Syndax Pharmaceuticals in a report on Tuesday. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.80.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.